CD30⁺ leukemic cutaneous T-cell lymphoma

J Am Acad Dermatol. 2021 Feb;84(2):530-532. doi: 10.1016/j.jaad.2020.05.014. Epub 2020 May 11.

Authors

Ariana Ellis¹, Luisa F Christensen², Timmie Sharma², Howard Meyerson³, Honda Kord², Kevin D Cooper²

Affiliations

¹ Northeast Ohio Medical University, Rootstown, Ohio; Department of Dermatology, University Hospitals Cleveland Medical Center/Case Western Reserve University School of Medicine, Cleveland, Ohio. Electronic address: aellis1@neomed.edu.
² Department of Dermatology, University Hospitals Cleveland Medical Center/Case Western Reserve University School of Medicine, Cleveland, Ohio.
³ Department of Pathology, University Hospitals Case Medical Center and Seidman Cancer Center Case Western Reserve University, Cleveland, Ohio.

PMID: 32437721
DOI: 10.1016/j.jaad.2020.05.014

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Bexarotene / administration & dosage
Humans
Ki-1 Antigen / analysis*
Ki-1 Antigen / metabolism
Male
Middle Aged
Mycosis Fungoides / blood
Mycosis Fungoides / diagnosis*
Mycosis Fungoides / drug therapy
Mycosis Fungoides / pathology
Photopheresis
Sezary Syndrome / blood
Sezary Syndrome / diagnosis*
Sezary Syndrome / drug therapy
Sezary Syndrome / pathology
Skin Neoplasms / blood
Skin Neoplasms / diagnosis*
Skin Neoplasms / drug therapy
Skin Neoplasms / pathology
T-Lymphocytes / metabolism
Treatment Outcome
Vorinostat / administration & dosage

Substances

Ki-1 Antigen
Vorinostat
Bexarotene